Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) EBITDA Margin: 2017-2025

Historic EBITDA Margin for Organogenesis Holdings (ORGO) over the last 9 years, with Sep 2025 value amounting to 13.74%.

  • Organogenesis Holdings' EBITDA Margin rose 832.00% to 13.74% in Q3 2025 from the same period last year, while for Sep 2025 it was -1.80%, marking a year-over-year increase of 101.00%. This contributed to the annual value of -0.27% for FY2024, which is 316.00% down from last year.
  • Latest data reveals that Organogenesis Holdings reported EBITDA Margin of 13.74% as of Q3 2025, which was up 210.34% from -12.45% recorded in Q2 2025.
  • Over the past 5 years, Organogenesis Holdings' EBITDA Margin peaked at 19.15% during Q2 2021, and registered a low of -30.85% during Q1 2025.
  • Moreover, its 3-year median value for EBITDA Margin was -1.27% (2023), whereas its average is -1.77%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first skyrocketed by 3,674bps in 2021, then crashed by 2,735bps in 2025.
  • Organogenesis Holdings' EBITDA Margin (Quarterly) stood at 15.45% in 2021, then tumbled by 790bps to 7.55% in 2022, then plummeted by 882bps to -1.27% in 2023, then soared by 934bps to 8.07% in 2024, then surged by 832bps to 13.74% in 2025.
  • Its last three reported values are 13.74% in Q3 2025, -12.45% for Q2 2025, and -30.85% during Q1 2025.